Global pharma major Lupin Limited (Lupin) has carved out its consumer healthcare business, LupinLife Consumer Healthcare Ltd. (LCH), into a wholly owned subsidiary.

Anil Kaushal will lead the new independent entity as Chief Executive Officer, the company announced on July 1, 2025.

Lupin noted that the move aligns with their broader strategy to establish a specialised consumer healthcare entity, with an enhanced focus on India’s rapidly growing self-care market.

Speaking on the development, Nilesh Gupta, Managing Director, Lupin said, “This strategic move reinforces our mission of developing high-impact businesses that drive sustained value. LCH exemplifies our unwavering dedication to patient-centric care and service to consumers.”

Originally launched in 2017, LupinLife served as Lupin’s consumer healthcare arm, offering a range of scientifically crafted over-the-counter (OTC) wellness products that support digestive health, nutrition, and everyday wellbeing. Its portfolio includes key products such as Softovac, Beplex Forte, Corcium and Aptivate.

Anil V Kaushal, CEO, LupinLife, commented, “This carve-out marks an exciting new chapter in our consumer healthcare journey. We are committed to offering world-class OTC products and wellness solutions for Indian consumers. LCH is well-positioned to scale with agility, innovate with intent, and expand access to wellness solutions across India.”

Lupin believes the new structure enable enhanced focus with targeted investments, leading to increased consumer impact, market expansion, and accelerated growth.

Headquartered in Mumbai, Lupin is a global pharmaceutical leader with products distributed in over 100 markets. It specialises in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients.